title: Respiratory syncytial virus.
abstract: RSV is now understood to be the most significant viral respiratory pathogen of infants and is capable of causing both bronchiolitis and pneumonia. It is a particular risk to hospitalized infants as the virus is easily spread through close contact. The most vulnerable infants are those who suffer with either congenital heart disease or bronchopulmonary dysplasia who easily fall prey to pulmonary complications of infection. Strict environmental control and the use of protective clothing and eyewear should be implemented to decrease the nosocomial spread of RSV. Available diagnostic studies include viral isolation, fluorescent antibody stains, and enzyme immunoassays. Treatment of the disease is usually supportive but hospitalized patients frequently benefit from aerosolized ribavirin therapy. Hopefully, current vaccine trials will be successful and this pathogen will not only be treatable but will also be preventable.
authors.affiliation: Department of Internal Medicine, University of South Florida College of Medicine, Tampa.
authors.forename: J T
authors.initials: JT
authors.lastname: Sinnott
authors.forename: L S
authors.initials: LS
authors.lastname: Gilchrist
authors.forename: L
authors.initials: L
authors.lastname: Ellis
mesh_terms: D002675:Child, Preschool; D006801:Humans; D007223:Infant; D012136:Respiratory Syncytial Viruses; D012141:Respiratory Tract Infections / Q000453:epidemiology* / Q000209:etiology; D010253:Respirovirus Infections / Q000453:epidemiology* / Q000517:prevention & control; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D012254:Ribavirin